Healthcare Industry News: Olympus
News Release - September 14, 2010
AngioDynamics Strengthens Executive Team with Key AppointmentsALBANY, N.Y.--(Healthcare Sales & Marketing Network)--AngioDynamics (NASDAQ: ANGO ) today announced the appointment of Scott Solano as Senior Vice President and Chief Technology Officer, and Scott Etlinger to the position of Senior Vice President, Global Operations. Mr. Solano will lead worldwide research, product development and intellectual property activities. Mr. Etlinger will have responsibility for manufacturing, sourcing and global supply chain management. The appointments are effective immediately, and Mr. Solano and Mr. Etlinger will join the Company’s executive leadership team, reporting directly to Jan Keltjens, AngioDynamics’ President and Chief Executive Officer.
“These key appointments further strengthen AngioDynamics’ management team and add experience that sharpens the Company’s focus on growth, innovation and execution,” Mr. Keltjens said. “Under Scott Solano’s leadership, we expect to further accelerate the stream of new products coming from our R&D organization that are designed to drive future sales growth. In addition, with the appointment of Scott Etlinger, we have added the necessary leadership and global experience to implement operational strategies required to achieve our growth and profitability objectives.”
Mr. Solano previously served as President and Chief Executive Officer of Arterial Vascular Engineering, a 6,000-person company focused on cardiovascular stents that was acquired by Medtronic, Inc. Additionally, Mr. Solano worked at Medtronic for over seven years in executive positions of increasing responsibility in technology management, new product development and operations, primarily in the Company’s Interventional Vascular business. Earlier in his career, Mr. Solano gained R&D and engineering leadership experience at C. R. Bard Inc., Mallinckrodt Medical and Olympus. He earned his Master of Science degree in Biomedical Engineering from Rensselaer Polytechnic Institute.
Mr. Etlinger previously served as Chief Operating Officer of Dental Services Group, a leading dental services and manufacturing company. Prior to that, he was the Senior Vice President of Global Operations and a member of the senior leadership team at American Medical Systems. Mr. Etlinger also was previously with Zimmer (formerly Centerpulse Orthopedics), a leader in orthopedic implants, for a decade, starting as Global Financial Controller before rising to Vice President, Global Supply Chain. He earned his MBA from St. Edwards University in Austin, Texas.
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. AngioDynamics’ diverse product lines include market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2010. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.